Cornelia Haag-Molkenteller
Chief Tech/Sci/R&D Officer at UROVANT SCIENCES LTD.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Robinson | M | 54 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| Sef P. Kurstjens | M | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 years |
| Christine Ocampo | F | 51 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 7 years |
| James Hindman | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 4 years |
| Shigeyuki Nishinaka | M | 59 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 years |
| Nori Ebersole | F | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 26 years |
| Ryan Kubota | M | - | - | |
| Ajay Bansal | M | 62 | 5 years | |
| Myrtle Potter | F | 65 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Pierre Legault | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 years |
| Jim Hindman | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 4 years |
| Walt Johnston | M | - | 4 years | |
| Kenton Stewart | M | - | 4 years | |
| Yuichiro Haruyama | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 years |
| Alex Thurman | M | 54 | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Scott Giacobello | M | 54 | 7 years | |
| Paul Bisaro | M | 63 | 5 years | |
| Brenton Saunders | M | 56 | 6 years | |
| David Adam Buchen | M | 59 | 1 years | |
| Keith Katkin | M | 52 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 years |
| Andrew L. Turner | M | 77 | 2 years | |
| David Hovland | M | - | 8 years | |
| John Kelly | M | 57 | 6 years | |
| Daphne Karydas | F | 49 | 3 years | |
| Nesli Basgoz | M | 66 | 6 years | |
| C. Nicholson | M | 69 | 6 years | |
| Roger J. Lias | M | 63 | 6 years | |
| Ambrose Bailey | M | 60 | 6 years | |
| Jirí Michal | M | 71 | 2 years | |
| Joseph H. Boccuzi | M | 77 | 3 years | |
| Christopher Coughlin | M | 71 | 6 years | |
| Bryan Smith | M | 45 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 years |
| Peter John McDonnell | M | 66 | 5 years | |
| Sigurdur Olafsson | M | 55 | 4 years | |
| Jonathon Kellerman | M | - | 6 years | |
| Hafrun Fridriksdottir | M | 62 | 14 years | |
| Christopher Bodine | M | 68 | 11 years | |
| James H. Bloem | M | 73 | 5 years | |
| Tamar Howson | F | 75 | 9 years | |
| George Frederick Wilkinson | M | 68 | 1 years | |
| Robert Todd Joyce | M | 66 | 1 years | |
| Michael R. Gallagher | M | 77 | 2 years | |
| Adriane Brown | M | 65 | 3 years | |
| John A. King | M | 74 | 2 years | |
| Patrick O’Sullivan | M | 82 | 5 years | |
| Megan Schoeps | F | 40 | 2 years | |
| Lisa Metzner | F | 55 | 3 years | |
| Abbey Jenkins | F | - | 2 years | |
| Sue-Jean Lin | F | 65 | 26 years | |
| Karah Parschauer | F | 46 | 11 years | |
| John W. LaRocca | M | 59 | 1 years | |
| Jonathan Garen | M | 58 | - | |
| Sanjiv Patel | M | 50 | 11 years | |
| David Bharucha | M | 62 | 4 years | |
| David Melnick | M | 72 | - | |
| Kathryn DiMarco | F | 57 | 5 years | |
| Sailaja Puttagunta | M | 55 | 1 years | |
| Herm Cukier | M | 57 | 5 years | |
| Yao Lee | M | 54 | 4 years | |
| Daina Schmidt | F | 62 | 9 years | |
| Ian A. Critchley | M | - | 3 years | |
| Daniel Motto | M | - | 6 years | |
| Matthew Moore | M | 51 | 5 years | |
| Kathleen Reape | M | 58 | 1 years | |
| Karen Ling | F | 60 | 5 years | |
| Michael Towers | M | - | 5 years | |
| Todd Branning | M | 54 | 3 years | |
| Dwight Moxie | M | 48 | 5 years | |
| Carlos Campoy | M | 60 | 2 years | |
| Michael Dunne | M | 64 | 1 years | |
| George Brady | M | - | - | |
| Sigurd Kirk | M | 57 | 8 years | |
| Matthew Walsh | M | 57 | 2 years | |
| Carolyn Myers | M | 66 | 6 years | |
| Charles M. Mayr | M | 67 | 3 years | |
| James D'Arecca | M | 53 | 7 years | |
| Jack Michelson | M | 89 | 1 years | |
| Patrick Spicer | M | - | - | |
| Laurent Fischer | M | 60 | 4 years | |
| Maria Hilado | F | 59 | 4 years | |
| Richard Spivey | M | 74 | 5 years | |
| James O'Brien | M | 57 | 3 years | |
| William Meury | M | 56 | 6 years | |
| William Kane | M | 62 | 7 years | |
| Gavin R. Corcoran | M | 61 | 4 years | |
| Robert Stewart | M | 56 | 9 years | |
| Dimitrios Angelis | M | 54 | 4 years | |
| Michael Rowe | M | 62 | 6 years | |
| Pamela Vig | M | 53 | - | |
| Leonard Dove | M | 51 | 2 years | |
| Enrico Cipro Vanni | M | 73 | - | |
| Elisabeth Sandoval | F | 62 | 23 years | |
| Michael McFadden | M | 57 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 1 years |
| Jeffrey D. Nornhold | M | 58 | 7 years | |
| Paul Navarre | M | - | - | |
| Eric Lefebvre | M | 60 | 2 years | |
| Lisa M. DeFrancesco | F | 45 | - | |
| Tina Devries | M | 63 | 1 years | |
| Thomas Nee | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Ireland | 85 | 85.86% |
| United States | 13 | 13.13% |
| United Kingdom | 10 | 10.10% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Cornelia Haag-Molkenteller
- Personal Network
